HCW 9206
Alternative Names: HCW-9206Latest Information Update: 19 Aug 2024
At a glance
- Originator HCW Biologics
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 15 replacements; Interleukin 7 replacements; Interleukin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 14 Aug 2024 Preclinical development is ongoing the US
- 28 Jun 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 05 Mar 2021 Wugen in-licenses HCW 9206 from HCW Biologics, prior to March 2021 (HCW Biologics pipeline, March 2021)